This program is supported by an independent education grant from Pfizer. This education program is only available to healthcare professionals in the USA.
Credits: AMA PRA Category 1 Credits™ (0.25.00 hours)
Type of activity: Enduring material (On-demand)
Launch date: September 16th 2026
Expiration date: December 31st 2027
Estimated time to complete this activity: 15 minutes
Prefer to read instead? Read our Key Clinical Summary here.
This is Module 2 of a three-part on-demand series: Module 1 and Module 3.
Activity Description
Join expert Dr. Alicia Morgans, MD, MPH, for a practical, case-based exploration of how to translate PARP inhibitor clinical trial evidence into targeted treatment decisions for patients with metastatic prostate cancer. This session unpacks the biological rationale of synthetic lethality when combining PARP and androgen receptor (AR) pathway inhibition, guiding clinicians through the complex landscape of PARP inhibitor approvals across disease states. Through real-world clinical cases, participants will learn how to weigh the profound efficacy seen in BRCA-altered disease against the more nuanced data in non-BRCA homologous recombination repair (HRR) alterations, manage regimen-specific toxicities, and determine the optimal sequencing of targeted therapies.
Session Highlights
- Understand the biological mechanism of AR-PARP crosstalk and how AR inhibition can induce a BRCA-like state, providing the rationale for combination therapy.
- Evaluate key trial data (including PROpel, MAGNITUDE, and TALAPRO-2) to navigate the crucial gap between broad clinical trial populations and the narrower, biomarker-specific FDA-approved indications.
- Proactively manage regimen-specific adverse events, particularly grade 3–4 anemia, by utilizing appropriate dose modifications to maintain treatment continuity.
- Assess the clinical trade-offs of using upfront PARP inhibitor combinations versus reserving monotherapy for later lines, taking into account the significant risk of patient attrition as the disease progresses.
Who Should Participate?
This program is designed for healthcare professionals directly involved in the diagnosis, targeted treatment, and longitudinal management of patients with metastatic prostate cancer (mPC), who seek to implement guideline-concordant genomic testing and multidisciplinary care into routine clinical practice.
- Oncology and Urology Practitioners (Academic and Community)
- Oncology Nurses
- Nurse Practitioners
- Physician Assistants
- Pharmacists
- Genetic Counselors
- Other Healthcare Professionals involved in the care and treatment of patients with mPC
Faculty
Dr Alicia Morgans
Dr Alicia Morgans is a Genitourinary Medical Oncologist and Director of the Survivorship Program at Dana-Farber Cancer Institute. Her clinical and research expertise focuses on improving outcomes and quality of life for men living with prostate cancer. Her research explores the long-term complications of systemic therapy, including skeletal, cardiovascular, metabolic, and cognitive effects, while incorporating patient-reported outcomes, preferences, and beliefs into clinical decision-making. Dr Morgans is also actively involved in prostate cancer treatment guidelines and survivorship initiatives, supporting more personalized, patient-centered approaches to care..
Continuing Education Information
Commercial support: This activity received monetary support through an independent education grant from Pfizer.
This continuing education activity will be provided by AffinityCE and MedAll. This activity will provide continuing education credit for physicians. A statement of participation is available to other attendees.
Disclosures
Dr Alicia Morgans has disclosed financial relationships within the past 24 months with the following ineligible companies: Consultant: AstraZeneca, Astellas, Bayer, Curium, Exelixis, Janssen, Lantheus, Macrogenics, Merck, Novartis, Pfizer, Telix, Tolmar, Sanofi, and Sumitomo Pharma America, Inc.; and receiving grant/research support from Astellas, Bayer, Janssen, Pfizer, Sumitomo Pharma America, Inc.
These disclosures are made in accordance with ACCME standards to ensure transparency and objectivity in continuing education.
Dr Morgans does not intend to discuss non-FDA uses of drug products and/or devices only in relation to products for which he has no financial relationships.
AffinityCE staff, MedAll staff, as well as planners and reviewers, have no relevant financial relationships with ineligible companies to disclose.
Mitigation of Relevant Financial Relationships
AffinityCE adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible companies. All relevant financial relationships for anyone associated with the content of this activity were mitigated prior to the release of this program.
Activity Accreditation for Health Professions
Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physician Assistants
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.
AffinityCE designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.
Nurses & Other Professionals
All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.
System Requirements
Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.
Unapproved and/or off-label use disclosure
AffinityCE/MedAll requires CE faculty to disclose to the participants:
- When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and
- Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
CME Inquiries
For all CME policy-related inquiries, please contact us at ce@affinityced.com.
Participation Costs
There is no cost to participate in this program.
This continuing education activity is active starting September 16th 2026, and will expire on December 31st 2027..
Estimated time to complete this activity: 15 minutes.